Background/Aims: Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease. We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation. Methods: The two 24-week studies were multicenter Phase 2 trials in patients under standard-of-care. In PYR-206, patients were randomized 1:1 and had baseline serum creatinine (bSCr) ≤2.0 mg/dl. In PYR-205/207, randomization was 2:1 and bSCr was ≤2.0 for PYR-205 and ≧2.0 but ≤3.5 mg/dl for PYR-207. Treated patients (122 active, 90 placebo) received 50 mg pyridoxamine twice daily in PYR-206; PYR-205/207 patients were escalated to 250 mg twice daily. Results: Adverse events were balanced between the groups (p = NS). Slight imbalances, mainly in the PYR-205/207 groups, were noted in deaths (from diverse causes, p = NS) and serious adverse events (p = 0.05) that were attributed to pre-existing conditions. In a merged data set, pyridoxamine significantly reduced the change from baseline in serum creatinine (p < 0.03). In patients similar to the RENAAL/IDNT studies (bSCr ≧1.3 mg/dl, type 2 diabetes), a treatment effect was observed on the rise in serum creatinine (p = 0.007). No differences in urinary albumin excretion were seen. Urinary TGF-β1 also tended to decrease with pyridoxamine (p = 0.049) as did the CML and CEL AGEs. Conclusion: These data provide a foundation for further evaluation of this AGE inhibitor in DN.

Keywords:
Diabetic nephropathy, Pyridoxamine, Serum creatinine, Urinary transforming growth factor-beta 1, Advanced glycation end products, Phase 2 clinical studies, pyridoxamine
1.
Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003;12:273–282.
2.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
3.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
4.
Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
5.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
6.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT-EDIC) Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389.
7.
Raj DS, Choudhury D, Welbourne TC, et al: Advanced glycation end products: a nephrologist’s perspective. Am J Kidney Dis 2000;35:365–380.
8.
Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38(4 suppl 1):S100–S106.
9.
Forbes JM, Cooper ME, Oldfield MD, et al: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 suppl 3):S254–S258.
10.
Monnier VM, Bautista O, Kenny D, et al: Skin collagen glycation, glycoxidation, and cross-linking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Relevance of glycated collagen products versus HBA1c as markers of diabetic complications. Diabetes 1999;48:870–880.
11.
Genuth S, Sun W, Cleary P, et al: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 2 diabetes. Diabetes 2005;54:3103–3111.
12.
Beisswenger PJ, Drummond KS, Nelson RG, et al: Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005;54:3274–3281.
13.
Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223–234.
14.
Williams ME: New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003;41(3 suppl 1):S42–S47.
15.
Thorpe SR, Baynes JW: Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003;25:275–281.
16.
Januszewski AS, Alderson NL, Metz TO, et al: Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003;31(Pt 6):1413–1416.
17.
Thornalley PJ: Dicarbonyl intermediates in the Maillard reaction. Ann N Y Acad Sci 2005;1043:111–117.
18.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.
19.
Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625.
20.
Vlassara H, Striker LJ, Teichberg S, et al: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704–11708.
21.
Youssef S, Nguyen DT, Soulis T, et al: Effect of diabetes and aminoguanidine therapy on renal advanced glycation end product binding. Kidney Int 1999;55:907–916.
22.
Monnier VM: Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003;419:1–15.
23.
Kelly DJ, Gilbert RE, Cox AJ, et al: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001;12:2098–2105.
24.
Nakamura S, Tachikawa T, Tobita K, et al: An inhibitor of advanced glycation end product formation reduces (carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003;41(suppl 3):S68–S71.
25.
Abdel-Rahman E, Bolton WK: Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002;11:565–574.
26.
Bolton WK, Cattran DC, Williams ME, et al: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32–40.
27.
Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251–258.
28.
Metz TO, Alderson NL, Thorpe SR, et al: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41–49.
29.
Voziyan PA, Hudson BG: Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62:1671–1681.
30.
Khalifah RG, Chen Y, Wassenberg JJ: Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005;1043:793–806.
31.
Degenhardt TP, Alderson NL, Arrington DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939–950.
32.
Alderson NL, Chachich ME, Frizzell N, et al: Effect of antioxidants and ACE inhibition on chemical modifications of proteins and progression of diabetic nephropathy in the streptozotocin diabetic rat. Diabetologia 2004;47:1385–1395.
33.
Zheng F, Leclercq B, Elliot SJ, et al: Reduction of glomerular lesions and albuminuria in db/db mice with established diabetic nephropathy following pyridoxamine treatment (abstract). J Am Soc Nephrol 2002;13:534A.
34.
Leclercq B, Zheng F, Berho M, et al: Decreased mortality and albuminuria following pyridoxamine and enalapril therapy in an obese mouse model for type 2 diabetes mellitus with established nephropathy (abstract). J Am Soc Nephrol 2003;14:396A.
35.
Zheng F, Zeng YJ, Plati AR, et al: Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70:507–514.
36.
de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309–2320.
37.
Moe SM, Chertow GM, Coburn JW, et al: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760–771.
38.
Chuang-Stein C: Safety analysis in controlled clinical trials. Drug Inf J 1998;32:1363S–1372S.
39.
Degenhardt TP, Grass L, Reddy S, et al: Technical note: the serum concentration of the advanced glycation end product Nε-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997;52:1064–1067.
40.
Ziyadeh FN, Hoffman BB, Han DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015–8029.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.